Last reviewed · How we verify

Bupivacaine plus Lidocaine

University of Alabama at Birmingham · FDA-approved active Small molecule

Bupivacaine and lidocaine are local anesthetics that block sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses.

Bupivacaine and lidocaine are local anesthetics that block sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses. Used for Local and regional anesthesia for surgical and diagnostic procedures, Pain relief in infiltration anesthesia.

At a glance

Generic nameBupivacaine plus Lidocaine
Also known asLidoderm, Xylocaine, Recticare, Anecream, Lmx4, Akten,, Marcaine and Sensorcaine, Marcaine Xylocaine
SponsorUniversity of Alabama at Birmingham
Drug classLocal anesthetic combination
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaAnesthesia / Pain Management
PhaseFDA-approved

Mechanism of action

Both drugs are amide-class local anesthetics that work by inhibiting sodium influx through voltage-gated sodium channels in the neuronal cell membrane. This prevents depolarization and action potential generation, thereby blocking sensory and motor nerve conduction in a localized area. The combination formulation provides complementary pharmacokinetics, with lidocaine offering faster onset and bupivacaine providing longer duration of action.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: